临床视角下抗肿瘤药物特殊用法的合理性研究进展

Advance in the rationality of unconventional application of anti-tumor drugs from clinical perspective

恶性肿瘤已成为全球第二大死亡原因,药物治疗是肿瘤治疗的重要手段之一。随着肿瘤治疗理念和临床实践的快速推进,抗肿瘤药物已经不只局限于传统的细胞毒性药物,以细胞受体、关键基因调控分子为靶点的新型抗肿瘤药物已应用于临床;在应用上,药品说明书往往滞后于临床实践,严格遵循药品说明书中的传统用法已无法满足肿瘤治疗实践的需求,一些具有高级别循证医学证据的用法未能及时在药品说明书中明确规定。因此,在充分理论和实践证据支持的基础上对抗肿瘤药物超说明书用法、含新型抗肿瘤药物联合用法以及妊娠期癌症用药等特殊用法进行综述,以期为临床规范用药提供参考。

Malignant tumor has become the second leading cause of death in the world and drug therapy is one of the important means of tumor treatment. With the rapid development of tumor therapy concept and clinical practice, anti-tumor drugs are not limited to traditional cytotoxic drugs. New anti-tumor drugs targeting cell receptors and key gene regulatory molecules have been applied in clinical practice. Drug instructions often lag behind clinical practice. The traditional usage of drug instructions can no longer meet the needs of oncology treatment practice and some usages with high level evidence-based medicine evidence are not clearly stipulated in drug instructions in time. Therefore, on the basis of sufficient theoretical and practical evidence support, the off-label use of anti-tumor drugs, the combined use of new anti-tumor drugs, and the special use of cancer drugs in pregnancy were reviewed in order to provide reference for rational drug use.